Skip to content

N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers

N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00967005
Enrollment
28
Registered
2009-08-27
Start date
2009-09-30
Completion date
2014-08-31
Last updated
2023-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gambling, Tobacco Use Disorder

Keywords

N acetyl cysteine, Pathological gambling, Nicotine dependence

Brief summary

The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and pathological gamblers (PG) symptoms in nicotine dependent pathological gamblers.

Detailed description

Among US adults, 12.8% report nicotine dependence, and nicotine dependence is highly associated with a variety of DSM-IV Axis I and II disorders (Grant BF et al., 2004). Pathological gambling (PG), a serious public health problem with detrimental effects on individuals and families, and with an estimated yearly cost to society of 5 billion dollars due to lost jobs, debt, bankruptcy, and incarcerations, is associated with elevated proportions of nicotine dependence (41% - 55%), and tobacco smoking in clinical samples of pathological gamblers has been associated with increased gambling severity and more frequent psychiatric problems (Smart & Ferris, 1996; Crockfod & El-Guebaly, 1998; Shaffer et al., 1999; Petry & Oncken, 2002; Potenza et al., 2004; Grant et al., 2005; Falk et al., 2006; Fagan et al., 2007). In addition, research suggests that continued nicotine use is associated with greater rates of relapse among pathological gamblers who received behavioral therapy. Despite increased awareness of the relationship between nicotine dependence and PG, and the possible effects of nicotine dependence on gambling severity, no previous research has focused on how assessment and treatment of nicotine dependence may aid in the successful treatment of PG or smoking cessation. Preliminary research suggests that behavioral therapy using imaginal desensitization and motivational interviewing (IDMI) has shown promise in reducing the symptoms of PG (Grant et al., in press). Despite the efficacy of treatments for PG and nicotine dependence, relapse is common among individuals with nicotine dependence and PG. Preclinical studies have suggested that levels of glutamate within the nucleus accumbens mediate reward-seeking behavior and may underlie relapse seen in addictions. N-acetyl cysteine, a dietary supplement, amino acid and cysteine pro-drug, appears to modulate glutamate within the nucleus accumbens and has shown benefit in reducing the reward-seeking behavior in individuals with cocaine dependence and in pathological gamblers (Baker et al., 2003; LaRowe et al., 2006; Grant et al., 2006). If successful in treating nicotine dependent pathological gamblers, N-acetyl cysteine may serve as a viable, low-cost, and easily available treatment option for nicotine dependent pathological gamblers who receive behavioral therapy. We therefore propose to examine how a dietary supplement, N-acetyl cysteine, used in combination with behavioral therapy, will affect both the urge to smoke and gamble in nicotine dependent pathological gamblers and smoking and gambling behaviors. We therefore propose a randomized placebo-controlled trial of N-acetyl cysteine or placebo with 80 nicotine dependent pathological gamblers who will all receive brief standardized smoking cessation treatment (Ask, Advise, and Refer model) for nicotine cessation and 6 sessions of IDMI for PG. We hypothesize that N-acetyl cysteine plus behavioral therapy will result in greater reduction in both nicotine dependence and PG symptoms during the acute treatment phase and will enhance greater long-term abstinence. Our research will contribute to an improved understanding of the treatment of nicotine-dependent pathological gamblers as well as a greater understanding of the treatment of co-occurring addictions. If our intervention is successful, it will have the potential to set a new standard of care for a range of psychiatric disorders that co-occur with nicotine dependence.

Interventions

N-Acetyl Cysteine, 1200mg-3000mg each day for 24-weeks

OTHERSugar Pill

placebo control

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
University of Minnesota
CollaboratorOTHER
University of Chicago
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Male and female outpatients, age 18-75 years; 2. Presence of current DSM-IV nicotine dependence and PG for at least 6 months duration; 3. Stable psychotropic drug dose for a period of at least 3 months prior to study entry; 4. Completion of complete blood count, urinalysis, liver function tests, thyroid function tests, and pregnancy test with no evidence of significant lab abnormalities; 5. Signed informed consent

Exclusion criteria

1. Subjects who are currently receiving individual or group therapy specifically for nicotine dependence or PG symptoms; 2. Currently receiving pharmacotherapies for either nicotine dependence or pathological gambling; 3. Subjects who have started attending Gamblers Anonymous within the 3 months prior to study initiation; 4. Subjects who have an unstable and significant medical illness; 5. Current clinically significant suicidality (score or 3 or 4 on item 3 of the Hamilton Depression Rating Scale) or any other disorder requiring immediate intervention; 6. Lifetime history of bipolar disorder type I or II, dementia, or psychotic disorder; 7. Current (past 12 months) DSM-IV substance abuse or dependence (except nicotine dependence); 8. Borderline or antisocial personality disorder based on the SCID-II; 9. Positive urine drug screen at screening; 10. Asthma (given possible worsening of asthma due to NAC); 11. Cognitive impairment that interferes with the capacity to understand and self-administer medication or provide written informed consent; 12. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential; and 13. Previous treatment with NAC

Design outcomes

Primary

MeasureTime frameDescription
Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total ScoreWeek 0Week 0 corresponds to baseline. Minimum score=0 and maximum score=40, with higher score signifying more severe symptoms. Scale is 10 items scored from 0 to 4. Scores on each item are summed to compute total score. Thoughts/urges (questions 1 to 5) and behavior (questions 6 to 10) are added to get the total score.
Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts SubscaleWeek 0Week 0 corresponds to baseline. Questions 1 through 5 are summed to compute the thoughts/urges subscale. Minimum=0 and maximum=20, with higher scores signifying more severe thoughts/urges.
Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior SubscaleWeek 0Week 0 corresponds to baseline. Questions 6 through 10 are summed to compute the thoughts/urges subscale. Minimum=0 and maximum=20, with higher scores signifying more severe gambling behaviors.
Fagerstrom Test for Nicotine Dependence Total ScoreWeek 0Week 0 corresponds to baseline. This scale has 6 questions. Questions 1 and 4 are on a scale from 0 to 3 (higher scores being more severe symptoms) and questions 2, 3, 5, and 6 are on a scale from 0 to 1 (1 being more severe symptoms). Scores on all questions are summed to compute total score, with higher total score meaning more severe nicotine dependence. Scores range from 0 to 10.
Hamilton Depression Rating Scale Total ScoreWeek 0Week 0 corresponds to baseline. This scale assesses depressed mood, feelings of guilt, difficulty sleeping, somatic symptoms, and others. Total score is computed by summing the scores of the 17 items. Minimum score is 0 and maximum score is 52, with higher scores signifying more severe depressive symptoms.
Hamilton Anxiety Rating Scale Total ScoreWeek 0Week 0 corresponds to baseline. This scale measures anxiety symptoms, tension, somatic symptoms, difficulty concentrating, and others. Total score is computed by summing the scores on the 14 items (each item is scored from 0 to 4). Minimum score= 0 and maximum score= 56, with higher scores signifying more severe anxiety symptoms.

Countries

United States

Participant flow

Participants by arm

ArmCount
N Acetyl Cysteine
The objective of this application is to examine whether, given its mechanism of action, the dietary supplement, N-acetyl cysteine (NAC) will reduce both tobacco use and PG symptoms in nicotine dependent pathological gamblers. N Acetyl Cysteine: N-Acetyl Cysteine, 1200mg-3000mg each day for 24-weeks
13
Sugar Pill
Sugar Pill: placebo control
15
Total28

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up710

Baseline characteristics

CharacteristicN Acetyl CysteineSugar PillTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
13 Participants15 Participants28 Participants
Age, Continuous47.5 years
STANDARD_DEVIATION 10.1
47.7 years
STANDARD_DEVIATION 10.6
47.6 years
STANDARD_DEVIATION 10.9
Region of Enrollment
United States
13 participants15 participants28 participants
Sex: Female, Male
Female
2 Participants3 Participants5 Participants
Sex: Female, Male
Male
11 Participants12 Participants23 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 130 / 15
serious
Total, serious adverse events
0 / 130 / 15

Outcome results

Primary

Fagerstrom Test for Nicotine Dependence Total Score

Week 0 corresponds to baseline. This scale has 6 questions. Questions 1 and 4 are on a scale from 0 to 3 (higher scores being more severe symptoms) and questions 2, 3, 5, and 6 are on a scale from 0 to 1 (1 being more severe symptoms). Scores on all questions are summed to compute total score, with higher total score meaning more severe nicotine dependence. Scores range from 0 to 10.

Time frame: Week 0

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineFagerstrom Test for Nicotine Dependence Total Score6.5 units on a scaleStandard Deviation 2
Sugar PillFagerstrom Test for Nicotine Dependence Total Score6.7 units on a scaleStandard Deviation 2.1
Primary

Fagerstrom Test for Nicotine Dependence Total Score

Week 24 represents the 3-month follow-up period (ie, corresponds to being off N-acetylcysteine or placebo and done with imaginal desensitization and motivational interviewing for 12 weeks). This scale has 6 questions. Questions 1 and 4 are on a scale from 0 to 3 (higher scores being more severe symptoms) and questions 2, 3, 5, and 6 are on a scale from 0 to 1 (1 being more severe symptoms). Scores on all questions are summed to compute total score, with higher total score meaning more severe nicotine dependence. Scores range from 0 to 10.

Time frame: Week 24

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineFagerstrom Test for Nicotine Dependence Total Score4.6 units on a scaleStandard Deviation 1.3
Sugar PillFagerstrom Test for Nicotine Dependence Total Score5.3 units on a scaleStandard Deviation 1.2
Primary

Fagerstrom Test for Nicotine Dependence Total Score

Week 12 corresponds to end of 6 sessions of N-acetylcysteine plus imaginal desensitization and motivational interviewing versus placebo plus imaginal desensitization and motivational interviewing. This scale has 6 questions. Questions 1 and 4 are on a scale from 0 to 3 (higher scores being more severe symptoms) and questions 2, 3, 5, and 6 are on a scale from 0 to 1 (1 being more severe symptoms). Scores on all questions are summed to compute total score, with higher total score meaning more severe nicotine dependence. Scores range from 0 to 10.

Time frame: Week 12

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineFagerstrom Test for Nicotine Dependence Total Score5.3 units on a scaleStandard Deviation 2.9
Sugar PillFagerstrom Test for Nicotine Dependence Total Score5.0 units on a scaleStandard Deviation 1.5
Primary

Fagerstrom Test for Nicotine Dependence Total Score

Week 6 corresponds to end of N-acetylcysteine plus Ask-Advise-Refer therapy versus placebo plus Ask-Advise-Refer therapy. This scale has 6 questions. Questions 1 and 4 are on a scale from 0 to 3 (higher scores being more severe symptoms) and questions 2, 3, 5, and 6 are on a scale from 0 to 1 (1 being more severe symptoms). Scores on all questions are summed to compute total score, with higher total score meaning more severe nicotine dependence. Scores range from 0 to 10.

Time frame: Week 6

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineFagerstrom Test for Nicotine Dependence Total Score4.0 units on a scaleStandard Deviation 1.9
Sugar PillFagerstrom Test for Nicotine Dependence Total Score5.9 units on a scaleStandard Deviation 2.4
Primary

Hamilton Anxiety Rating Scale Total Score

Week 24 represents the 3-month follow-up period (ie, corresponds to being off N-acetylcysteine or placebo and done with imaginal desensitization and motivational interviewing for 12 weeks). This scale measures anxiety symptoms, tension, somatic symptoms, difficulty concentrating, and others. Total score is computed by summing the scores on the 14 items (each item is scored from 0 to 4). Minimum score= 0 and maximum score= 56, with higher scores signifying more severe anxiety symptoms.

Time frame: Week 24

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineHamilton Anxiety Rating Scale Total Score5.0 units on a scaleStandard Deviation 3.6
Sugar PillHamilton Anxiety Rating Scale Total Score6.5 units on a scaleStandard Deviation 5.2
Primary

Hamilton Anxiety Rating Scale Total Score

Week 0 corresponds to baseline. This scale measures anxiety symptoms, tension, somatic symptoms, difficulty concentrating, and others. Total score is computed by summing the scores on the 14 items (each item is scored from 0 to 4). Minimum score= 0 and maximum score= 56, with higher scores signifying more severe anxiety symptoms.

Time frame: Week 0

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineHamilton Anxiety Rating Scale Total Score11.1 units on a scaleStandard Deviation 10.8
Sugar PillHamilton Anxiety Rating Scale Total Score9.7 units on a scaleStandard Deviation 6.6
Primary

Hamilton Anxiety Rating Scale Total Score

Week 6 corresponds to end of N-acetylcysteine plus Ask-Advise-Refer therapy versus placebo plus Ask-Advise-Refer therapy. This scale measures anxiety symptoms, tension, somatic symptoms, difficulty concentrating, and others. Total score is computed by summing the scores on the 14 items (each item is scored from 0 to 4). Minimum score= 0 and maximum score= 56, with higher scores signifying more severe anxiety symptoms.

Time frame: Week 6

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineHamilton Anxiety Rating Scale Total Score7.5 units on a scaleStandard Deviation 4.3
Sugar PillHamilton Anxiety Rating Scale Total Score6.2 units on a scaleStandard Deviation 4
Primary

Hamilton Anxiety Rating Scale Total Score

Week 12 corresponds to end of 6 sessions of N-acetylcysteine plus imaginal desensitization and motivational interviewing versus placebo plus imaginal desensitization and motivational interviewing. This scale measures anxiety symptoms, tension, somatic symptoms, difficulty concentrating, and others. Total score is computed by summing the scores on the 14 items (each item is scored from 0 to 4). Minimum score= 0 and maximum score= 56, with higher scores signifying more severe anxiety symptoms.

Time frame: Week 12

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineHamilton Anxiety Rating Scale Total Score7.4 units on a scaleStandard Deviation 3.2
Sugar PillHamilton Anxiety Rating Scale Total Score4.2 units on a scaleStandard Deviation 3.2
Primary

Hamilton Depression Rating Scale Total Score

Week 24 represents the 3-month follow-up period (ie, corresponds to being off N-acetylcysteine or placebo and done with imaginal desensitization and motivational interviewing for 12 weeks). This scale assesses depressed mood, feelings of guilt, difficulty sleeping, somatic symptoms, and others. Total score is computed by summing the scores of the 17 items. Minimum score is 0 and maximum score is 52, with higher scores signifying more severe depressive symptoms.

Time frame: Week 24

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineHamilton Depression Rating Scale Total Score2.8 units on a scaleStandard Deviation 2.1
Sugar PillHamilton Depression Rating Scale Total Score3.5 units on a scaleStandard Deviation 1.7
Primary

Hamilton Depression Rating Scale Total Score

Week 12 corresponds to end of 6 sessions of N-acetylcysteine plus imaginal desensitization and motivational interviewing versus placebo plus imaginal desensitization and motivational interviewing. This scale assesses depressed mood, feelings of guilt, difficulty sleeping, somatic symptoms, and others. Total score is computed by summing the scores of the 17 items. Minimum score is 0 and maximum score is 52, with higher scores signifying more severe depressive symptoms.

Time frame: Week 12

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineHamilton Depression Rating Scale Total Score7.0 units on a scaleStandard Deviation 4.9
Sugar PillHamilton Depression Rating Scale Total Score3.7 units on a scaleStandard Deviation 3.2
Primary

Hamilton Depression Rating Scale Total Score

Week 6 corresponds to end of N-acetylcysteine plus Ask-Advise-Refer therapy versus placebo plus Ask-Advise-Refer therapy. This scale assesses depressed mood, feelings of guilt, difficulty sleeping, somatic symptoms, and others. Total score is computed by summing the scores of the 17 items. Minimum score is 0 and maximum score is 52, with higher scores signifying more severe depressive symptoms.

Time frame: Week 6

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineHamilton Depression Rating Scale Total Score7.5 units on a scaleStandard Deviation 4.7
Sugar PillHamilton Depression Rating Scale Total Score5.5 units on a scaleStandard Deviation 3.8
Primary

Hamilton Depression Rating Scale Total Score

Week 0 corresponds to baseline. This scale assesses depressed mood, feelings of guilt, difficulty sleeping, somatic symptoms, and others. Total score is computed by summing the scores of the 17 items. Minimum score is 0 and maximum score is 52, with higher scores signifying more severe depressive symptoms.

Time frame: Week 0

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineHamilton Depression Rating Scale Total Score9.7 units on a scaleStandard Deviation 5.7
Sugar PillHamilton Depression Rating Scale Total Score7.9 units on a scaleStandard Deviation 4.8
Primary

Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale

Week 0 corresponds to baseline. Questions 6 through 10 are summed to compute the thoughts/urges subscale. Minimum=0 and maximum=20, with higher scores signifying more severe gambling behaviors.

Time frame: Week 0

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale11.7 units on a scaleStandard Deviation 3.7
Sugar PillYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale11.4 units on a scaleStandard Deviation 2.8
Primary

Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale

Week 6 corresponds to end of N-acetylcysteine plus Ask-Advise-Refer therapy versus placebo plus Ask-Advise-Refer therapy. . Questions 6 through 10 are summed to compute the thoughts/urges subscale. Minimum=0 and maximum=20, with higher scores signifying more severe gambling behaviors.

Time frame: Week 6

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale8.5 units on a scaleStandard Deviation 5.7
Sugar PillYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale8.3 units on a scaleStandard Deviation 4.9
Primary

Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale

Week 12 corresponds to end of 6 sessions of N-acetylcysteine plus imaginal desensitization and motivational interviewing versus placebo plus imaginal desensitization and motivational interviewing. Questions 6 through 10 are summed to compute the thoughts/urges subscale. Minimum=0 and maximum=20, with higher scores signifying more severe gambling behaviors.

Time frame: Week 12

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale2.0 units on a scaleStandard Deviation 3.1
Sugar PillYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale2.8 units on a scaleStandard Deviation 4.5
Primary

Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale

Week 24 represents the 3-month follow-up period (ie, corresponds to being off N-acetylcysteine or placebo and done with imaginal desensitization and motivational interviewing for 12 weeks). Questions 6 through 10 are summed to compute the thoughts/urges subscale. Minimum=0 and maximum=20, with higher scores signifying more severe gambling behaviors.

Time frame: Week 24

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale0.2 units on a scaleStandard Deviation 0.4
Sugar PillYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Behavior Subscale2.8 units on a scaleStandard Deviation 4.1
Primary

Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score

Week 6 corresponds to end of N-acetylcysteine plus Ask-Advise-Refer therapy versus placebo plus Ask-Advise-Refer therapy. Minimum score=0 and maximum score=40, with higher score signifying more severe symptoms. Scale is 10 items scored from 0 to 4. Scores on each item are summed to compute total score. Thoughts/urges (questions 1 to 5) and behavior (questions 6 to 10) are added to get the total score.

Time frame: Week 6

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score17.4 units on a scaleStandard Deviation 9.1
Sugar PillYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score16.3 units on a scaleStandard Deviation 7.4
Primary

Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score

Week 12 corresponds to end of 6 sessions of N-acetylcysteine plus imaginal desensitization and motivational interviewing versus placebo plus imaginal desensitization and motivational interviewing. Minimum score=0 and maximum score=40, with higher score signifying more severe symptoms. Scale is 10 items scored from 0 to 4. Scores on each item are summed to compute total score. Thoughts/urges (questions 1 to 5) and behavior (questions 6 to 10) are added to get the total score.

Time frame: Week 12

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score7.5 units on a scaleStandard Deviation 4.6
Sugar PillYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score5.5 units on a scaleStandard Deviation 5.9
Primary

Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score

Week 24 represents the 3-month follow-up period (ie, corresponds to being off N-acetylcysteine or placebo and done with imaginal desensitization and motivational interviewing for 12 weeks). Minimum score=0 and maximum score=40, with higher score signifying more severe symptoms. Scale is 10 items scored from 0 to 4. Scores on each item are summed to compute total score. Thoughts/urges (questions 1 to 5) and behavior (questions 6 to 10) are added to get the total score.

Time frame: Week 24

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score1.0 units on a scaleStandard Deviation 1.3
Sugar PillYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score6.4 units on a scaleStandard Deviation 6.2
Primary

Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score

Week 0 corresponds to baseline. Minimum score=0 and maximum score=40, with higher score signifying more severe symptoms. Scale is 10 items scored from 0 to 4. Scores on each item are summed to compute total score. Thoughts/urges (questions 1 to 5) and behavior (questions 6 to 10) are added to get the total score.

Time frame: Week 0

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score23.5 units on a scaleStandard Deviation 6.4
Sugar PillYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score20.4 units on a scaleStandard Deviation 5
Primary

Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale

Week 24 represents the 3-month follow-up period (ie, corresponds to being off N-acetylcysteine or placebo and done with imaginal desensitization and motivational interviewing for 12 weeks). Questions 1 through 5 are summed to compute the thoughts/urges subscale. Minimum=0 and maximum=20, with higher scores signifying more severe thoughts/urges.

Time frame: Week 24

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale0.8 units on a scaleStandard Deviation 1.2
Sugar PillYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale3.6 units on a scaleStandard Deviation 3.6
Primary

Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale

Week 6 corresponds to end of N-acetylcysteine plus Ask-Advise-Refer therapy versus placebo plus Ask-Advise-Refer therapy. Questions 1 through 5 are summed to compute the thoughts/urges subscale. Minimum=0 and maximum=20, with higher scores signifying more severe thoughts/urges.

Time frame: Week 6

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale8.9 units on a scaleStandard Deviation 4.2
Sugar PillYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale7.9 units on a scaleStandard Deviation 3.8
Primary

Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale

Week 12 corresponds to end of 6 sessions of N-acetylcysteine plus imaginal desensitization and motivational interviewing versus placebo plus imaginal desensitization and motivational interviewing. Questions 1 through 5 are summed to compute the thoughts/urges subscale. Minimum=0 and maximum=20, with higher scores signifying more severe thoughts/urges.

Time frame: Week 12

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale5.5 units on a scaleStandard Deviation 2.3
Sugar PillYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale2.7 units on a scaleStandard Deviation 2.1
Primary

Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale

Week 0 corresponds to baseline. Questions 1 through 5 are summed to compute the thoughts/urges subscale. Minimum=0 and maximum=20, with higher scores signifying more severe thoughts/urges.

Time frame: Week 0

ArmMeasureValue (MEAN)Dispersion
N Acetyl CysteineYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale11.8 units on a scaleStandard Deviation 3.7
Sugar PillYale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Urges/Thoughts Subscale9.0 units on a scaleStandard Deviation 3.4

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026